Potentiation of the therapeutic index of interleukin-2 immunotherapy by combination with taurine in a syngeneic murine tumour model

Irish Journal of Medical Science

Volumn 171, Issue 2, 2002, Pages 85-88

  Finnegan, N ^b,c   Toomey, D ^b,c   Condron, C ^b,c   Redmond, H P ^a,b,c   Da Costa, M ^b,c   Bouchier Hayes, D J ^b,c  

^a Department of Medicine National University of Ireland Cork   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; RECOMBINANT INTERLEUKIN 2; SODIUM CHLORIDE; TAURINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRY WEIGHT; FEMALE; IMMUNOTHERAPY; LUNG CANCER; LUNG INJURY; LUNG LAVAGE; LUNG METASTASIS; LUNG NODULE; MELANOMA B16; MOUSE; NONHUMAN; ORGAN WEIGHT; TUMOR MODEL; VASCULAR DISEASE;

EID: 0036553658     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03168959     Document Type: Article

References (30)

1. Rosenberg SA, Mule JJ, Speiss RJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumour mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 1985; 161: 1169-88.
2. Rosenberg SA, Lotze MT, Muul LM. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889-97.
3. Ettinghausen SE, Rosenberg SA. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant IL-2. Cancer Res 1986: 46; 2784-92.
4. Schuchter LM, Esa AH, May WS et al. Successful treatment of murine melanoma with bryostatin1. Cancer Res 1991; 51: 682-87.
5. Whitehead RP, Friedman KD, Clark DA, Pagani K, Rapp L. Phase I trial of simultaneous administration of interleukin 2 and interleukin-4 subcutaneously. Clin Cancer Res 1995; 1: 1145-52.
6. Mier JW. Abrogation of interleukin-2 toxicity. In: Therapeutic applications of Interleukin-2. New York: Marcel Dekker Inc., 1995: p 455-475.
7. Nishio S-I, Negoro S, Hosokawa T et al. The effect of taurine on age-related immune decline in mice: the effect of taurine on T cell and B cell proliferative response under costimulation with ionomycin and phorbol myristate acetate. In: Mechanisms of Aging and Development. Ireland Elsevier Scientific Publishers Ltd. 1990: p 125-139.
8. Huxtable, R. Physiological actions of taurine. Physiol Rev 1992; 72: 101-63.
9. Wang JH, Redmond HP, Watson RWG, Condron CC, Bouchier-Hayes D. The beneficial effects of taurine on the prevention of human endothelial cell death. Shock 1996; 6: 331-38.
10. Watson RWG, Redmond HP, Bouchier-Hayes D. Taurine up-regulates antimicrobial function of human inflammatory cells through a calcium-dependent mechanism. Surg Forum 1994; 80: 573-75.
11. Damle NK, Doyle LV, Bender JR, Bradley EC. Interleukin-2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol 1987; 138: 1779-85.
12. Kitayama J, Tsuno N, Yasuhara H, et al. Lysis of endothelial cells by autologous lymphokine-activated killer cells. J Immunol 1994; 38: 317-22.
13. Fujita S, Puri RK, Yu Z-X. Travis WD, Ferrans VJ. An ultrastructural study of in-vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2. Cancer 1991; 68: 2169-74.
14. Richards AL, Djeu JY. Calcium-dependent natural killer and calcium-independent natural cytotoxic activities in an IL-2-dependent killer cell line. J Immunol 1990; 145: 3144-49.
15. Ryan JC, Niemi EC, Goldfien RD, Hiserodt JC, Seaman WE. NKR-P1, an activating molecule on rat natural killer cells, stimulates phosphoinositide turnover and a rise in intracellular calcium. J Immunol 1991; 147: 3244-50.
16. Kotasek D, Vercellotti GM, Ochoa AC et al. Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells. Cancer Res 1988; 48: 5528-32.
17. Finnegan N, Redmond HP, Bouchier-Hayes D. Taurine attenuates recombinant IL-2 activated, lymphocyte mediated endothelial cell injury. Cancer Res 1998; 82: 186-99.
18. Rinehart JJ, Triozzi PL, Lee MH, Aldrich W, Young D. Modulation of hematologic and immunologic effects of high dose chemotherapy by IL-2 in a murine tumour model. Mol Biother 1992; 4: 77-82.
19. Lode HN, Xiang R, Varki NM et al. Targeted IL-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 1997; 89: 1586-94.
20. Cheever MA, Thompson JA, Kern DE, Greenberg PD. Interleukin 2 (IL 2) administered in vivo: influence of IL-2 route and timing on T cell growth. J Immunol 1985; 134: 3895-900.
21. Da Costa ML, Redmond HP, Bouchier-Hayes D. The effect of laparotomy and laparoscopy on the establishment of spontaneous tumour metastases. Surgery 1998; 124: 516-21.
22. Da Costa, ML, Redmond HP, Bouchier-Hayes D. Taurolidene improves survival by abrogating the accelerated development and proliferation of solid tumours and development of organ metastases from circulating tumour cells released following surgery. J Surg Res 2001; 101: 1-9.
23. Peto R, Pike MC, Armitage P et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
24. Mastino A, Favalli C, Grelli S, Innocenti F, Garaci E. Thymosin potentiates interleukin 2-induced cytotoxic activity in mice. Cellular Immunol 1991; 133: 196-205.
25. Sznol M, Thurn A, Aronson FR. Interleukin-2 in combination with other biologic agents. In: Therapeutic applications of Interleukin-2, New York, Marcel Dekker Inc. 1993: p 233-75.
26. Silva MA, Cunha GM, Viana GS, Rao VS. Taurine modulates chemical nociception in mice. Braz J Med Biol Res 1993; 26: 1319-24.
27. Nakajima I, Ozaki M, Jinnai H et al. Enhanced activity against syngeneic murine tumours by intrasplenic injection of recombinant interleukin-2 (IL-2) and interleukin-1 (IL-1). Cancer Biotherapy 1993; 8: 319-26.
28. Puri RK, Leland P. In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice. Clin Exp Immunol 1991; 85: 317-25.
29. Finnegan N. The role of taurine in vitro. In: The role of taurine in IL-2 immunotherapy. PhD Thesis, TCD Dublin. 1998; 71-88.
30. Milei J, Ferreira R, Llesuy S et al. Reduction of reperfusion injury with preoperative rapid intravenous infusion of taurine during myocardial revascularisation. Am Heart J 1992; 123: 339-45.